Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 okt 2008 - 19:05
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
Bericht
Additional Milestone Achieved in Collaboration Agreement with sanofi pasteur
Leiden, The Netherlands, 1 October 2008 – Dutch biopharma company
Crucell N.V. today announced the preliminary results of the first phase II clinical
study of its investigational rabies monoclonal antibody combination, which started
on 31 March 2008 in the US.
Crucell has a collaboration and commercialization agreement with sanofi pasteur,
the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal
antibodies to be used in combination with rabies vaccine for post-exposure
prophylaxis against this fatal disease.
Gerelateerde downloads
Datum laatste update: 21 februari 2026